AstraZeneca unveils new R&D centre in Hong Kong
The R&D centre will focus on cell and gene therapy studies.
UK-based biopharmaceutical company AstraZeneca has launched a research and development (R&D) centre in Hong Kong.
The R&D centre in Hong Kong will focus on research and development of medicines in cell and gene therapy.
AstraZeneca also launched the Hong Kong iCampus, which will assist startups to broaden the medical innovation ecosystem.
AstraZeneca also organised a group of 80 Mainland pharmaceutical and biotechnology enterprises to visit Hong Kong.
The group comprises large-scale listed enterprises and startups engaging in pioneering pharmaceutical technologies.